Abstract：Objective To observe and evaluate the clinical effect of amoxicillin/clavulanate potassium combined levofloxacin in multi-drug resistant tuberculosis(MDR-TB). Methods 101 cases of retreatment smear-positive MDR-TB patients were randomly divided into treatment group(52 patients) and control group(49 patients); chemotherapy: the treatment group based on amoxicillin/clavulanate potassium and levofloxacin, associated with pyrazinamide, ethambutol, aminosalicylic acid isoniazid and rifampicin spray bite; The control group based on levofloxacin, combination therapy is same with the treatment group; The treatment course of all cases is 12 months. Results 5 patients were terminated because of adverse drug reactions In the course of treatment, the treatment group actually completed 50 patients, the control group actually completed 46 patients. To the end of treatment, sputum conversion rate of treatment group and control group Separately was 78.0% and 56.5%, sputum conversion rate in the treated group was significantly higher than the control group(P <0.05); foci effective rate of treatment group was 78.0%, cavity closure rate was 82.0%, foci effective rate and cavity closure rate in treatment group were significantly higher than the control group(P <0.05). Conclusion amoxicillin/clavulanate potassium combined levofloxacin in the treatment of MDR-TB was contribute to sputum conversion and Absorption of the lesion, adverse drug reactions was low, worthy of clinical application.
王晓, 刘幸, 王璐. 阿莫西林/克拉维酸钾联合左氧氟沙星治疗耐多药肺结核临床疗效分析[J]. 中国药物警戒, 2011, 8(9): 521-523.
WANG Xiao, LIU Xing, WANG Lu. Clinical Efficacy Analysis of Amoxicillin/clavulanic Potassium Combined Levofloxacin in the treatment of multi-drug resistant tuberculosis (MDR-TB). Chinese Journal of Pharmacovigilance, 2011, 8(9): 521-523.
[1] Bl ower S M, Chou T1.Modeling the emergence of the"hot z ones" :tuberculosis and the amp lificati on dynamics of drug resistance[J]. Nature Medicine, 2004, 10 (10):1111-1116. [2] 徐瑛.耐多药结核病研究进展[J].预防医学情报杂志,2008, 24(4): 290-293. [3] 黄钥藩,杨仪,陈尊杰,等.含左旋氧氟沙星方案治疗耐多药肺结核疗效分析[J].临床荟萃, 2004 ,19(12):663-665. [4] Ersoz G,Karasu Z,Yildiz C,et al.Severe toxic hepatitis associated with amoxycillin and clavulanic acid[J].Clin Pharm Ther,2001,26(3):225. [5] Mrowka C. Munch R. Rezzonico M, et al.Acute segmental hemorrhagic penicollin-associated colitis[J].Dtsch Med Wochenschr, 1990,115(46):1750. [6] Desgrandchamps D,Schnyder C. Severe neutropenia in prolonged treatment with orallyadministeredAugmentin(amoxicillin/clavula- nicacid)[J].Infection,1987,15(4):260. [7] 杨立荣.左氧氟沙星治疗耐多药肺结核临床疗效分析[J].中国实用医药, 2008, 3(14):86-87. [8] 何解生,章静. 阿莫西林/克拉维酸钾的临床应用[J].海峡药学, 2006,18(2)：136-137. [9] 温贵华,薛碧媚,熊礼宽,等. 结核分枝杆菌抗生素快速药敏测定[J].中国公共卫生,2005,21(5):556-557. [10] John Crofton ,Piere Chaulet ,Dermot Maher. 耐药结核病管理的指导方针[M].世界卫生组织出版,2000,29-33. [11] 中国防痨协会.耐多药结核病化学治疗的意见(试行)[J].中国防痨杂志,2003 ,25(1) :4-5.
2011, Vol. 8 
